

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Purinergic Signaling in Kidney Disease

Citation for published version: Menzies, R, Tam, FWK, Unwin, RJ & Bailey, M 2016, 'Purinergic Signaling in Kidney Disease', *Kidney International*. https://doi.org/10.1016/j.kint.2016.08.029

Digital Object Identifier (DOI):

10.1016/j.kint.2016.08.029

Link:

Link to publication record in Edinburgh Research Explorer

Document Version: Peer reviewed version

Published In: Kidney International

Publisher Rights Statement:

This is the authors accepted manuscript as accepted by Elsevier on 15 August 2016

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Purinergic Signaling in Kidney Disease

Robert I. Menzies¹, Frederick W Tam², Robert J Unwin^{3,4} and Matthew A. Bailey¹

¹British Heart Foundation Centre for Cardiovascular Science, The University of Edinburgh, ²Imperial College Renal and Transplant Centre, Department of Medicine, Imperial College London, ³Cardiovascular and Metabolic Diseases (CVMD iMed) Biotech Unit, AstraZeneca Gothenburg, Sweden; ⁴UCL Centre for Nephrology, University College London, UK.

Running title: Renal purinoceptors

<u>Keywords</u>: ATP, adenosine, P2X, P2Y, adenosine, kidney, renal tubule, vasculature, inflammation

<u>Correspondence</u>: Robert Unwin UCL Centre for Nephrology, UCL Medical School Royal Free Campus Rowland Hill Street, London NW3 2PF, United Kingdom Email: robert.unwin@ucl.ac.uk

1 Abstract

2 Nucleotides are key subunits for nucleic acids and provide energy for intracellular metabolism. 3 They can also be released from cells to act physiologically as extracellular messengers or 4 pathologically as danger signals. Extracellular nucleotides stimulate membrane receptors in the 5 P2 and P1 family. P2X are ATP-activated cation channels; P2Y and P1 are G-protein coupled 6 receptors activated by ATP, ADP, UTP and UDP or adenosine, respectively. Renal P2 receptors 7 influence both vascular contractility and tubular function. Renal cells also express 8 ectonucleotidases that rapidly hydrolyze extracellular nucleotides. These enzymes integrate this 9 multi-receptor purinergic-signaling complex by determining the nucleotide milieu, as well as 10 titrating receptor activation.

Purinergic signaling also regulates immune cell function by modulating the synthesis and release of various cytokines such as IL1- β and IL-18 as part of inflammasome activation. Abnormal or excessive stimulation of this intricate paracrine system can be pro- or anti-inflammatory, and is also linked to necrosis and apoptosis. Kidney tissue injury causes a localized increase in ATP concentration, and sustained activation of P2 receptors can lead to renal glomerular, tubular and vascular cell damage. Purinergic receptors also regulate the activity and proliferation of fibroblasts, promoting both inflammation and fibrosis in chronic disease.

In this short review we summarize some of the recent findings related to purinergic signaling in the kidney. We focus predominantly on the P2X7 receptor, discussing why antagonists have so far disappointed in clinical trials and how advances in our understanding of purinergic signaling might help to reposition these compounds as potential treatments for renal disease.

22 Introduction

23 Since their discovery in the 1970s, P2 purinergic receptors (P2R) have evolved from an initially 24 contentious biological concept ¹, through to a progressive understanding of their complex 25 physiological actions, emerging now as attractive and 'druggable' targets for disease ^{2, 3}. To date, 26 the most advanced potential therapeutic P2R targets are antagonists for P2Y12R to inhibit 27 thrombosis ⁴, and P2X7R for the treatment of chronic inflammatory diseases such as 28 rheumatoid arthritis ⁵ and COPD ⁶. Several P2X7R antagonists have completed Phase 2 clinical 29 trials, but despite pre-clinical promise, these compounds have failed to deliver the expected 30 benefit and so interest in P2X7R has declined. In this concise review we cover purinergic 31 signaling in the kidney and explore the contribution of this system to renal physiology and 32 disease. The main focus is on the role of P2X receptors, particularly P2X7R, in renal injury and 33 disease. P2X7R can orchestrate interactions between the immune and vascular systems, and 34 defining this complex interaction as inflammation and injury develop may help us unlock the 35 potential of P2X7R antagonists as renal therapeutics.

36

37 P2 receptors and purinergic signaling in the kidney

38 Purinergic receptors are sub-classified as P1R that bind adenosine and P2R that are activated by 39 purine/pyrimidine nucleotides; P2R are in turn subdivided into P2YR and P2XR. The 8 P2YRs are 40 coupled to G-proteins and are activated with differing selectivity by adenosine triphosphate 41 (ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP). 42 The 7 P2XRs are trimeric ligand-gated ion channels activated by ATP, but not, or only weakly, by 43 ADP or adenosine monophosphate (AMP). The molecular properties of these receptors and 44 their ligands are described in detail in the IUPHAR/BPS Guide to Pharmacology: 45 http://www.guidetopharmacology.org.

46 P2 receptors are expressed in all segments of the nephron and renal cells often express multiple 47 receptor subtypes at both the apical and basolateral cell membranes ^{7,8}. Renal cells can also 48 release ATP and UTP into the extracellular space. This release is likely to be regulated and is 49 facilitated by several transport systems that involve vesicular or lysosomal exocytosis, or 50 channel-mediated release via connexins ⁹ or pannexins ¹⁰. Extracellular ATP and UTP have short 51 half-lives due to rapid catabolism by ectonucleotidases (Figure 1) that are also expressed by 52 renal cells ^{11, 12}. Their immediate breakdown products, ADP and UDP, are potent agonists at 53 P2Y1R,12R,13R, and P2Y6R,14R, respectively. Further metabolism of ADP produces the 5'AMP 54 (through CD39) and eventually adenosine (through CD73), the agonist at P1R (A1,2A,2B,3) that 55 are also present in renal epithelia. Thus, the kidney has complex and regulated machinery for 56 hierarchical purinergic signaling integrated by the action of ectonucleotidases. Ascribing specific 57 physiological functions to a given receptor subtype has been challenging: available receptor 58 agonists are not sufficiently selective and are often unstable ¹¹. In contrast, selective and 59 specific receptor antagonists are providing a pharmacological means of assessing the function(s) 60 of this system in vivo.

Extracellular nucleotides can influence a range of physiological functions, from cell-proliferation and growth, through to energy metabolism and transepithelial solute flux. These functions have been reviewed in depth recently ¹³ and we can provide only a brief overview. It is evident that abnormal P2R activity can occur in various inflammatory and non-inflammatory disease states ranging from hypertension ¹⁴ to transplant rejection, to polycystic kidney disease ¹⁵. However, more beguiling is the therapeutic potential for P2XR antagonists in chronic kidney disease (CKD).

67

68

70 P2 receptors control renal vascular and microvascular function

71 P2 receptors are expressed throughout the vasculature and microvasculature (Figure 2) and 72 strongly influence vessel function ¹⁶. The renal vasculature and microvasculature also expresses 73 NTPDase1 (CD39) that hydrolyses ATP to ADP and AMP, and thereby rapidly curtail purinergic 74 signaling ¹⁷. P2X1R is the dominant receptor in vascular smooth muscle and application of ATP 75 to the adventitia evokes contraction in the pre-glomerular vasculature ^{18, 19}. P2X1R null mice 76 display an attenuated pressure-induced constriction of the afferent arteriole ²⁰ and targeted 77 deletion of NTPDase1 prolongs the half-life of extracellular ATP, enhancing the vascular 78 response to increased pressure ²¹.

79 Direct renal artery infusion of ATP increases blood flow, causing vasodilation due to production of nitric oxide (NO) by the endothelium ²² and also NO-independent vasodilatation induced by 80 81 intra-renal prostanoids ²³. The P2 receptor subtype(s) that mediates the vasodilatatory response 82 to ATP is unknown. In human arterial endothelial cells and endothelial cells cultured from the 83 mouse pulmonary artery, P2X4R is the most abundantly expressed receptor, followed by P2X7R 84 ²⁴⁻²⁶. P2X4R mediates the release of NO in response to increased shear stress ²⁴. This response is 85 lost in P2X4R null mice, which have endothelial dysfunction and hypertension ²⁵. P2X7R 86 activation seems to promote a tonic vasoconstriction of both the pre-glomerular arteries and 87 medullary microcirculation ¹⁴, which is discussed more below. Other P2 receptors can influence 88 endothelial function, for example, vasodilatation caused by UDP is abolished in P2Y6R null mice 89 ²⁷. The descending vasa recta are also affected by extracellular nucleotides, since infusion of ATP into the renal artery reduces medullary blood flow as a result of P2X1R activation ²³, and 90 91 ATP released from sympathetic nerves causes constriction of vasa recta pericytes ²⁸.

93 Multiple P2R subtypes are expressed in glomerular cells (Figure 2). Under normal conditions, 94 P2YR predominate ²⁹ and extracellular nucleotides influence mesangial proliferation and 95 contraction, as well as contraction of the parietal sheet ²⁹. In podocytes, P2Y1R is the dominant 96 functional receptor as demonstrated by comprehensive pharmacological profiling and 97 immunolocalization ³⁰; however, recently P2X4R has been shown to have a mechano-sensitive 98 role affecting the podocyte actin cytoskeleton ³¹, although P2X4R knockout mice, while 99 hypertensive, have no obvious gross glomerular phenotype and are not known to be proteinuric. 100 In contrast, P2Y1R null mice are protected from acute nephrotoxic injury, showing preserved 101 renal function, reduced capillary rarefaction and fibrosis, and enhanced survival ³². P2Y1R 102 activation may, therefore, contribute to glomerular injury. P2X7R expression also seems to be 103 associated with glomerular injury, since it is increased in multiple glomerular cells types, 104 including inflammatory cells, in models of severe hypertension, type 1 diabetes ³³, and acute 105 inflammatory glomerulonephritis ³⁴. Uncovering the primary role of this increased glomerular 106 P2X7R expression remains an active area of research.

107

108 P2 receptors and renal tubular physiology

109 P2R exert a largely inhibitory effect on tubular electrolyte transport and this, together with 110 expression in specific nephron segments, has been reviewed extensively elsewhere ³⁵ and is 111 summarized in Figure 2. The processes are best defined for sodium flux, which is tonically 112 suppressed by P2R activation in several nephron segments ³⁶. It is likely that such paracrine 113 control by extracellular nucleotides provides a route for rapid modulation of tubular transport 114 that can link solute and fluid delivery to adaptive transport capacity, for example adenosinemediated tubuloglomerular feedback is impaired in CD73^{-/-} mice ³⁷. This form of control can 115 116 integrate with more slowly adapting hormonal systems, for example the renin-angiotensin-

121 **Proximal tubule**

122 The proximal tubule, which expresses apical P2Y1R and P2X5R, and basolateral P2Y4R and 123 P2Y6R ^{39, 40}, accounts for reabsorption of ~65% of the filtered sodium load. Extracellular 124 nucleotides inhibit the major sodium transporters in this segment, NHE3⁴¹, NaPi2⁴² and Na,K-ATPase ⁴³, and inhibition of transepithelial flux has been confirmed in vivo ⁴⁴. The ATP 125 126 concentration in tubular fluid is unknown, although measurements in bulk fluid collected from 127 the end of the proximal convoluted tubule (PCT) report concentrations of 100-300 nmol/l⁴⁵. The 128 brush border membrane expresses ENPP3 (ectonucleotide pyrophosphatase/ phospodiesterase 129 3) and ecto-5'-nucleotidase (NT5E; CD73)¹² that should terminate physiological signaling. 130 Microperfusion studies using nucleotide scavengers suggest that the 'ambient' concentration of 131 the physiological purinergic ligand, most probably ADP, is ~10µmol/l, exerting a tonic inhibitory 132 effect that may help to balance tubular sodium reabsorption with glomerular filtration ⁴⁴.

133

134 **The distal nephron**

135 Increased fluid flow or changes in osmolality of the tubular fluid promotes nucleotide secretion 136 in both the thick limb of Henle ⁴⁶ and collecting duct ⁴⁷, inhibiting transport in downstream 137 nephron segments. In the thick ascending limb of Henle (TALH), ATP release is dependent on 138 activation of the transient receptor potential cation channel TRPV4 osmosensor ⁴⁸. These 139 nucleotides activate endothelial NO synthase (NOS3) in thick limb cells, and P2R signaling 140 underpins the flow-dependent increase in NO production ⁴⁹ and subsequent inhibition of apical 141 NKCC2 and basolateral Na,K-ATPase activity ⁵⁰. Studies in knockout mice suggest P2X4R and
 142 P2Y2R contribute to this signaling arc ^{51, 52}.

Extracellular ATP has long been known to inhibit the epithelial sodium channel (ENaC), the ratelimiting step for sodium transport in the connecting tubule and collecting duct ⁵³. Studies in isolated segments show that ATP activates P2Y2R to reduce the open probability of ENaC ⁵⁴⁻⁵⁶. P2yr2 null mice lack the tonic suppression of ENaC and are hypertensive ⁵⁴. Studies *in vivo* suggest that P2X4R activation also inhibits ENaC ^{53, 57} and our own pilot studies in a P2X4R null mouse suggest that this receptor may be important in the modulation of sodium transport by aldosterone (Craigie et al, unpublished).

150

151 **P2R and blood pressure regulation**

152 Hypertension is a major modifiable risk factor for cardiovascular and renal disease and is highly 153 prevalent ⁵⁸. Human genetic studies have found an association between SNPs in P2XR encoding genes and blood pressure or cardiovascular disease. The loss of function variant rs28360472 in 154 155 P2RX4 associates with increased pulse pressure ⁵⁹, itself an important cardiovascular risk factor. 156 An intronic SNP (rs591874) in the gene encoding P2X7R is associated with elevated blood 157 pressure ⁶⁰. The loss of function variant rs3751143 is common (25% heterozygosity and up to 3% 158 homozygosity) and protects against ischemic stroke ⁶¹. The physiology of P2RX7 genetic 159 variation is almost certainly subtle, if not complex. For example, rs3751143 does not associate 160 with impaired endothelial dysfunction or vascular stiffness in essential hypertensives ⁶², but 161 does confer a significantly reduced sensitivity to P2X7R antagonism ⁶³.

Pressure-natriuresis is an important mechanism of long-term blood pressure control ⁶⁴ and is modulated by paracrine factors that inhibit sodium transport in the renal proximal tubule, including extracellular nucleotides. Microdialysis experiments reveal a direct relationship between renal artery perfusion pressure and the concentration of ATP in the interstitial fluid of 166 the kidney cortex ⁶⁵. As mentioned earlier, extracellular nucleotides inhibit the key transporters 167 in the proximal tubule ⁴¹⁻⁴³. This natriuretic effect is buttressed by inhibition of sodium transport 168 in the distal nephron. Increased flow through the collecting duct promotes ATP secretion to 169 inhibit ENaC. This ATP release is abolished in connexin 30 knockout mice, severely attenuating 170 the pressure-natriuresis response ⁹. Consistent with this, mice over-expressing human 171 NTPDase1 (CD39), a cell surface enzyme that scavenges extracellular nucleotides, display a small 172 impairment of the natriuretic response to a high sodium diet and concomitant aldosterone 173 infusion ⁶⁶. It is assumed that P2Y2R mediates the inhibitory effect of ATP on distal tubule 174 sodium transport. Receptor agonists have been considered as potential antihypertensives. 175 P2yr2 null mice display enhanced ENaC activity and are hypertensive. Surprisingly, blood 176 pressure is salt resistant ⁶⁷ and endothelial dysfunction with impaired NO release may be causal. 177 Recent studies also suggest that ATP can inhibit ENaC indirectly: in IMCD cells, activation of 178 P2X7R promotes synthesis of endothelin-1, which is pro-natriuretic due to ETB-mediated 179 inhibition of ENaC ⁶⁸. However, the significance of this cell line-based study is not clear, since 180 acute P2X7R antagonism *in vivo* improves the pressure-natriuresis relationship ¹⁴.

181 Although P2X7R activation contributes to the physiological control of blood pressure by the 182 kidney, sustained activation of the receptor, which does not de-sensitize with repeated 183 exposure to ATP, promotes hypertensive renal injury. Thus, prophylactic P2X7R antagonism ⁶⁹ or 184 'knock-out' of the murine P2X7k transcript ⁷⁰, which leaves several functional P2RX7 transcripts 185 intact ⁷¹, protects against the injury associated with salt-sensitive hypertension. P2X7R 186 antagonism/deletion reduced albuminuria and interstitial fibrosis, lowered blood pressure and 187 reduced the infiltration of T and B cells, macrophages and leucocytes. The mechanisms 188 underpinning these effects are not known, as discussed further below. Our data suggest that 189 P2X7R in the renal vasculature and microvasculature may impair blood pressure regulation by 190 the kidney ¹⁴. We identified elevated renal expression of P2X7R (and P2X4R) as a candidate gene

191 for hypertensive renal vascular injury in rats 72. P2X7R localized to the vascular and 192 microvascular endothelium down to afferent arterioles. The selective P2X7R antagonist 193 AZ11657312 increased renal medullary perfusion and improved tissue oxygenation in 194 angiotensin II-treated rats ¹⁴; these beneficial effects were partially dependent on NO synthesis. 195 Overall, activation of P2X7R induces microvascular dysfunction and regional hypoxia, 196 particularly under high angiotensin II tone. These effects are pro-inflammatory and may 197 contribute to progression of renal injury. In the next section, we discuss the role of P2X7R in 198 renal injury and disease and assess the potential for antagonists as renal therapeutics.

199

200 **P2XR and renal injury**

201 There is consistent pre-clinical evidence supporting a role for P2X7R in inflammation (Figure 3), 202 and, as already mentioned, P2X7R antagonists have been explored as a treatment target in 203 rheumatoid arthritis ⁵, COPD ⁶, and IBD ⁷³, but with mixed or generally disappointing results. This 204 has caused interest in the receptor to wax and wane. However, it is likely that an improved 205 understanding of the biological roles of P2X7R, including its unique two-stage ability to induce 206 membrane permeability to large (>900 Da) molecules, rather than cations alone, as well as the 207 regulation and function of the main splice variants, will provide a fresh impetus to the clinical 208 testing of antagonists.

In the normal kidney P2X7R is typically only present at low levels, often undetectable by RNA analysis in whole kidney extracts. The receptor is normally localized to certain compartments, particularly the vasculature and microvasculature, at least in the rat ^{7, 14, 72}. A wealth of data shows that injury/inflammation increases expression in renal cells. For example, TNFα can induce expression of P2X7R in cultured mesangial cells ⁷⁴. In renal biopsy material from patients with lupus nephritis, increased expression of P2X7R protein has been found ⁷⁵. Nevertheless, it

218 Glomerulonephritis

219 A more detailed characterization of the expression and potential function of P2X7R have been 220 carried out in rodent models of nephrotoxic nephritis (NTN) ⁷⁵. In a mouse model of accelerated 221 NTN, increased expression of P2X7R was co-localized to glomerular macrophages as well as 222 intrinsic glomerular cells. In NTN in WKY rats, onset P2X7R expression coincided with onset of 223 proteinuria. The inflamed glomeruli are infiltrated by macrophages showing the NLRP3 224 inflammasome activation ⁷⁶. The WKY strain of rat is known to be more susceptible to 225 developing severe and progressive glomerulonephritis when compared with the resistant LEW 226 rat strain. WKY and LEW rats have identical MHC genes, but have distinct genetic differences 227 and differences in their expression of P2X7R and the NLRP3 inflammasome ⁷⁶. More specifically, 228 bone marrow derived (BMD) macrophages from WKY rats have increased expression of P2X7R 229 protein and mRNA associated with increased expression of multiple genes of the NLRP3 230 inflammasome pathway, even in their basal state in vitro, again when compared with BMD 231 macrophages from LEW rats. Following priming with endotoxin and stimulation with 232 extracellular ATP, compared with LEW rats, macrophages from WKY rats have higher levels of 233 caspase-1 activation and secretion of more mature IL-1 β and IL-18. Thus, strain differences in 234 expression of P2X7R and subsequent downstream activation of the inflammasome may be 235 responsible for the difference in susceptibility to experimental glomerulonephritis.

The functional importance of P2X7R was investigated in gene knockout mice and with systemic treatment by a small molecule P2X7R antagonist ³⁴. Using the model of accelerated NTN, the P2X7R knockout mice had lower urinary monocyte chemoattract-1 (CCL2), fewer infiltrating 239 glomerular macrophages, less glomerular fibrin deposition and less proteinuria than in wild-type 240 mice. In NTN rats, treatment with the P2X7R antagonist A438079 significantly reduced 241 glomerular expression of CCL2, glomerular macrophage infiltration, glomerular fibrinoid 242 necrosis and proteinuria compared with vehicle-treated rats. However, exactly how P2X7R is 243 involved in antibody-mediated glomerulonephritis is unclear. Typically, extracellular ATP binds 244 to P2X7R in endotoxin-primed macrophages, resulting in inflammasome activation and release 245 of mature IL-1β and IL-18⁷⁷, yet endotoxin or other bacterial products are not involved in the 246 induction of NTN in WKY rats ³⁴. The interaction between immune complex stimulation and 247 P2X7R needs further investigation and to ascertain whether treatment with the P2X7R 248 antagonist after the onset of disease is effective in reducing the severity of glomerulonephritis. 249 There is also recent evidence in lupus prone mice that treatment with a P2X7R antagonist can 250 decrease the severity of renal injury and levels of dsDNA antibodies ⁷⁸.

251

252 Acute kidney injury

253 Renal ischemia-reperfusion injury (IRI) is a common occurrence in many clinical settings from 254 sepsis to major surgery, including renal transplantation. There is increased expression of P2X7R, 255 mainly in the renal tubules, in a mouse model of renal IRI; treatment with A438079 reduced 256 renal expression of chemokines (MCP-1 and RANTES), p-ERK, NGAL, renal tubular injury and cell 257 death ⁷⁹.

As well as the mentioned increase in P2X7R in a rat model of type 1 diabetes ³³, in a mouse model of high fat diet-induced metabolic disease, proteinuria and albuminuria developed in the wild-type mice, but not in P2X7a variant knockout mice ⁸⁰. In the high fat diet fed mice there was also increased renal expression of P2X7R and components of the NLRP3 inflammasome that were attenuated in the high fat diet fed P2X7R knockout mice, as was renal expression of chemokine CCL2, macrophage infiltration and expression of extracellular matrix protein.
 Moreover, increased expression of P2X7R and inflammasome components were found in renal
 tissue from patients with glomerulonephritis ⁷⁵.

266

267 Fibrosis

268 Purinergic signaling is involved in tissue remodeling (Figure 3) and several studies in various 269 tissues suggest that these pathways may also drive tissue fibrosis in chronic injury, one feature 270 of which is a sustained increase in ambient concentrations of ATP, ADP, UTP and UDP⁸¹. Tissue 271 fibroblasts express multiple P2R subtypes and respond to extracellular nucleotides by activating 272 key pathways for the production of extracellular matrix. In cardiac fibroblasts, for example, 273 P2Y2R activation is strongly pro-fibrotic ⁸², and activation of P2X4R and P2X7R promotes 274 ERK1/2-dependent fibroblast proliferation ⁸³. This cluster of P2Rs is also relevant to the kidney 275 in which fibroblasts and mesangial cells mainly determine ECM deposition. In this context, P2Y2R activation increases mesangial cell proliferation ⁷⁴ and P2X7R activation increases matrix 276 production by mesangial cells ⁸⁴. 277

278 The role of P2 receptors in renal fibrosis has been investigated in the unilateral ureteral 279 obstruction (UUO) model ⁸⁵. Transient expression of P2X7R was detected only in tubular 280 epithelial cells 7 days after induction of UUO in wild-type mice. The renal tubular expression of 281 TGF- β 1, macrophage infiltration, tubular apoptosis and tubulointerstitial fibrosis were reduced 282 in P2X7R knockout mice compared with wild-type mice by day 14. The role of the 283 inflammasome in this model has also been investigated. Knockout of apoptosis-associated 284 speck-like protein containing a caspase recruitment domain (ASC) in mice results in reduced 285 UUO-mediated tubulointerstitial fibrosis, together with fewer infiltrating inflammatory cells and 286 reduced renal expression of mRNA for IL-1β, CCL2, TGFβ1 and collagen I; however, it is not clear

how P2X7R may regulate TGF- β 1 expression ⁸⁶. While there is a well-established relationship between stimulation of P2X7R and activation of the inflammasome, it is not known what the priming signal is in the sterile UUO model and what triggers fibrogenesis.

P2X4R is closely related to P2X7R and there has been ongoing controversy over whether P2X4R and P2X7R can form heterotrimers ^{87, 88}. The potential importance of P2X4R in renal fibrosis has been investigated in the UUO model. Surprisingly, the P2X4R knockout mice showed increased renal fibrosis following induction of UUO associated with increased expression of TGFβ1 and connective tissue growth factor (CTGF, also known as CCN2), and increased amounts of type I collagen ⁸⁹. These results suggest that P2X7R is pro-fibrotic in this model and that P2X4R may have an anti-fibrotic role through its regulation of pro-fibrotic growth factors.

297 More recent studies show that nucleotidases may also contribute to fibrosis by regulating the 298 half-life of ATP. ENTPD1 (CD39)-null mice are more sensitive to ischemic tissue injury than wild-299 type mice ⁹⁰, because ATP persists and its hydrolysis to protective adenosine is blunted. 300 Similarly, these null mice have more pronounced renal injury in the IRI model ^{91, 92}; although in 301 this setting the role of adenosine is less certain, since the deletion of CD73, the enzyme that 302 converts AMP to adenosine, was also protective ⁹³. Overall, these data suggest that enzymes 303 involved in terminating P2R signaling may be less tractable as therapeutic targets than the 304 receptors themselves. Recent studies indicate that CD39 expression by T-reg lymphocytes is 305 essential for their pro-reparative role in response to chronic renal injury ⁹⁴.

306

307 What now for P2X7R antagonists?

P2X7R antagonists may have failed because of significant gaps in our knowledge about the complex processing and diverse roles of *P2XR7* gene products and the implications this may have for P2X7R in disease. Single nucleotide polymorphisms (SNPs) such as rs3751143 (causing Glu496Ala) can impair P2X7R function 95,96 : ATP-dependent IL-1 β release from lymphocytes is significantly suppressed in individuals carrying this SNP 97 . Alternative splicing can produce novel protein isoforms that are emerging as important factors in disease pathogenesis, as well as in determining the right treatment target 98 .

315 Human P2X7R has at least 10 splice isoforms, the functions of which have not been unraveled; 316 however, in rodents, the common 'k variant' of P2X7R is much more sensitive to ATP than the 317 original full-length 'a variant' ⁹⁹. Pre-clinical data suggest that genetic variation in P2X7R will 318 increase the population wide variance of both agonist and antagonist binding affinities, 319 suggesting that we need to re-evaluate or redefine clinical trials on the basis of the P2X7R 320 "fingerprint". The tissue distribution, regulation and function of these splice isoforms in the 321 healthy kidney is just beginning to be explored; the pharmacogenomics of P2X7R and the impact 322 of disease is largely unknown. The next phase of research will define these key biological 323 processes involving P2X7R, which may not all be 'bad' ¹⁰⁰, and provide a better understanding of 324 how isoform-specific receptor antagonists should be deployed in kidney disease. Is this P2X7R 325 Redux?

327 **References**:

329

331

334

337

342

346

349

352

355

358

361

364

367

370

373

- 328 1. Burnstock G. Purinergic nerves. *Pharmacol Rev* 1972; **24:** 509-581.
- 330 2. Burnstock G. Introduction: P2 receptors. *Curr Top Med Chem* 2004; **4:** 793-803.
- 332 3. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. *Purinergic* 333 *Signal* 2008; **4:** 1-20.
- van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible
 direct P2Y12 antagonists. *Semin Thromb Hemost* 2005; **31:** 195-204.
- 3385.Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7339purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid340arthritis in patients with active disease despite treatment with methotrexate or341sulphasalazine. Ann Rheum Dis 2012; **71:** 1630-1635.
- 3436.Eltom S, Stevenson CS, Rastrick J, et al. P2X7 receptor and caspase 1 activation are344central to airway inflammation observed after exposure to tobacco smoke. PLoS One3452011; 6: e24097.
- 3477.Menzies RI, Unwin RJ, Bailey MA. Renal P2 receptors and hypertension. Acta Physiol348(Oxf) 2015; 213: 232-241.
- Bailey MA, Hillman KA, Unwin RJ. P2 receptors in the kidney. *J Auton Nerv Syst* 2000; 81:
 264-270.
- 3539.Sipos A, Vargas SL, Toma I, et al. Connexin 30 deficiency impairs renal tubular ATP354release and pressure natriuresis. J Am Soc Nephrol 2009; 20: 1724-1732.
- 35610.Jackson MF. Interdependence of ATP signalling and pannexin channels; the servant was357really the master all along? *Biochem J* 2015; **472:** e27-30.
- Shirley DG, Vekaria RM, Sevigny J. Ectonucleotidases in the kidney. *Purinergic Signal* 2009; 5: 501-511.
- Vekaria RM, Shirley DG, Sevigny J, et al. Immunolocalization of ectonucleotidases along
 the rat nephron. Am J Physiol Renal Physiol 2006; 290: F550-560.
- 365 13. Burnstock G. Purinergic signalling: from discovery to current developments. *Exp Physiol* 366 2014; **99:** 16-34.
- 36814.Menzies RI, Howarth AR, Unwin RJ, et al. Inhibition of the purinergic P2X7 receptor369improves renal perfusion in angiotensin-II-infused rats. *Kidney Int* 2015; **88:** 1079-1087.
- 37115.Hillman KA, Woolf AS, Johnson TM, et al. The P2X7 ATP receptor modulates renal cyst372development in vitro. Biochem Biophys Res Commun 2004; **322:** 434-439.

37416.Inscho EW. ATP, P2 receptors and the renal microcirculation. Purinergic Signal 2009; 5:375447-460.

376

379

383

386

389

392

395

399

403

406

410

414

418

421

- Tr. Zhang Y, Morris KL, Sparrow SK, *et al.* Defective renal water handling in transgenic mice
 over-expressing human CD39/NTPDase1. *Am J Physiol Renal Physiol* 2012; **303:** F420-430.
- 18. Chan CM, Unwin RJ, Bardini M, et al. Localization of P2X1 purinoceptors by
 autoradiography and immunohistochemistry in rat kidneys. Am J Physiol 1998; 274:
 F799-804.
- 38419.Inscho EW, Cook AK, Imig JD, et al. Physiological role for P2X1 receptors in renal385microvascular autoregulatory behavior. J Clin Invest 2003; **112:** 1895-1905.
- 387 20. Inscho EW, Cook AK, Imig JD, *et al.* Renal autoregulation in P2X1 knockout mice. *Acta* 388 *Physiol Scand* 2004; **181**: 445-453.
- 39021.Kauffenstein G, Drouin A, Thorin-Trescases N, et al. NTPDase1 (CD39) controls391nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 2010; 85: 204-213.
- 39322.Eltze M, Ullrich B. Characterization of vascular P2 purinoceptors in the rat isolated394perfused kidney. Eur J Pharmacol 1996; **306:** 139-152.
- Eppel GA, Ventura S, Evans RG. Regional vascular responses to ATP and ATP analogues in
 the rabbit kidney in vivo: roles for adenosine receptors and prostanoids. *Br J Pharmacol* 2006; **149**: 523-531.
- 400 24. Yamamoto K, Korenaga R, Kamiya A, et al. P2X(4) receptors mediate ATP-induced
 401 calcium influx in human vascular endothelial cells. Am J Physiol Heart Circ Physiol 2000;
 402 279: H285-292.
- 40425.Yamamoto K, Sokabe T, Matsumoto T, et al. Impaired flow-dependent control of vascular405tone and remodeling in P2X4-deficient mice. Nat Med 2006; 12: 133-137.
- 407 26. Ray FR, Huang W, Slater M, et al. Purinergic receptor distribution in endothelial cells in
 408 blood vessels: a basis for selection of coronary artery grafts. Atherosclerosis 2002; 162:
 409 55-61.
- 411 27. Bar I, Guns PJ, Metallo J, *et al.* Knockout mice reveal a role for P2Y6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. *Mol Pharmacol* 2008;
 413 74: 777-784.
- 415 28. Crawford C, Kennedy-Lydon TM, Callaghan H, et al. Extracellular nucleotides affect
 416 pericyte-mediated regulation of rat in situ vasa recta diameter. Acta Physiol (Oxf) 2011;
 417 202: 241-251.
- 41929.Bailey MA, Turner CM, Hus-Citharel A, et al. P2Y receptors present in the native and420isolated rat glomerulus. Nephron Physiol 2004; 96: p79-90.

30. Ilatovskaya DV, Palygin O, Levchenko V, *et al.* Pharmacological characterization of the P2
receptors profile in the podocytes of the freshly isolated rat glomeruli. *Am J Physiol Cell Physiol* 2013; **305**: C1050-1059.

425

429

433

436

439

442

445

449

452

456

459

463

467

- 426 31. Forst AL, Olteanu VS, Mollet G, et al. Podocyte Purinergic P2X4 Channels Are
 427 Mechanotransducers That Mediate Cytoskeletal Disorganization. J Am Soc Nephrol 2016;
 428 27: 848-862.
- 430 32. Hohenstein B, Renk S, Lang K, *et al.* P2Y1 gene deficiency protects from renal disease
 431 progression and capillary rarefaction during passive crescentic glomerulonephritis. *J Am*432 Soc Nephrol 2007; **18:** 494-505.
- 434 33. Vonend O, Turner CM, Chan CM, et al. Glomerular expression of the ATP-sensitive P2X
 435 receptor in diabetic and hypertensive rat models. *Kidney Int* 2004; 66: 157-166.
- 43734.Taylor SR, Turner CM, Elliott JI, et al. P2X7 deficiency attenuates renal injury in438experimental glomerulonephritis. J Am Soc Nephrol 2009; 20: 1275-1281.
- 44035.Burnstock G, Evans LC, Bailey MA. Purinergic signalling in the kidney in health and441disease. Purinergic Signal 2014; 10: 71-101.
- 44336.Praetorius HA, Leipziger J. Intrarenal purinergic signaling in the control of renal tubular444transport. Annu Rev Physiol 2010; 72: 377-393.
- 446 37. Castrop H, Huang Y, Hashimoto S, et al. Impairment of tubuloglomerular feedback
 447 regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice. J Clin Invest 2004; 114:
 448 634-642.
- 45038.Stockand JD, Mironova E, Bugaj V, et al. Purinergic inhibition of ENaC produces451aldosterone escape. J Am Soc Nephrol 2010; 21: 1903-1911.
- 45339.Bailey MA, Imbert-Teboul M, Turner C, et al. Evidence for basolateral P2Y(6) receptors454along the rat proximal tubule: functional and molecular characterization. J Am Soc455Nephrol 2001; 12: 1640-1647.
- 45740.Bailey MA, Shirley DG. Effects of extracellular nucleotides on renal tubular solute458transport. Purinergic Signal 2009; 5: 473-480.
- 460 41. Bagorda A, Guerra L, Di Sole F, *et al.* Extracellular Adenine Nucleotides Regulate Na+/H+
 461 Exchanger NHE3 Activity in A6-NHE3 Transfectants by a cAMP/PKA-dependent
 462 Mechanism. *J Membr Biol* 2002; **188**: 249-259.
- 464 42. Lee YJ, Park SH, Jeung TO, *et al.* Effect of adenosine triphosphate on phosphate uptake in
 465 renal proximal tubule cells: involvement of PKC and p38 MAPK. *J Cell Physiol* 2005; **205**:
 466 68-76.
- 46843.Jin W, Hopfer U. Purinergic-mediated inhibition of Na+-K+-ATPase in proximal tubule469cells: elevated cytosolic Ca2+ is not required. Am J Physiol 1997; 272: C1169-1177.

47144.Bailey MA. Inhibition of bicarbonate reabsorption in the rat proximal tubule by
activation of luminal P2Y1 receptors. *Am J Physiol Renal Physiol* 2004; **287:** F789-796.

473

476

480

483

486

489

492

496

499

502

506

509

512

515

518

- 474 45. Vekaria RM, Unwin RJ, Shirley DG. Intraluminal ATP concentrations in rat renal tubules. J
 475 Am Soc Nephrol 2006; 17: 1841-1847.
- 46. Jensen ME, Odgaard E, Christensen MH, et al. Flow-induced [Ca²⁺]_i increase depends on nucleotide release and subsequent purinergic signaling in the intact nephron. J Am Soc Nephrol 2007; 18: 2062-2070.
- 48147.Bjaelde RG, Arnadottir SS, Overgaard MT, et al. Renal epithelial cells can release ATP by482vesicular fusion. Front Physiol 2013; 4: 238.
- 48448.Silva GB, Garvin JL. TRPV4 mediates hypotonicity-induced ATP release by the thick485ascending limb. Am J Physiol Renal Physiol 2008; 295: F1090-1095.
- 487 49. Silva G, Beierwaltes WH, Garvin JL. Extracellular ATP stimulates NO production in rat 488 thick ascending limb. *Hypertension* 2006; **47:** 563-567.
- 49050.Silva GB, Garvin JL. Extracellular ATP inhibits transport in medullary thick ascending491limbs: role of P2X receptors. Am J Physiol Renal Physiol 2009; 297: F1168-1173.
- 49351.Marques RD, de Bruijn PI, Sorensen MV, et al. Basolateral P2X receptors mediate494inhibition of NaCl transport in mouse medullary thick ascending limb (mTAL). Am J495Physiol Renal Physiol 2012; 302: F487-494.
- 49752.Marques RD, Praetorius HA, Leipziger J. P2Y2 receptor knock-out mice display normal498NaCl absorption in medullary thick ascending limb. Front Physiol 2013; 4: 280.
- 50053.Shirley DG, Bailey MA, Unwin RJ. In vivo stimulation of apical P2 receptors in collecting501ducts: evidence for inhibition of sodium reabsorption. Am J Physiol Renal Physiol 2005.
- 503 54. Pochynyuk O, Bugaj V, Rieg T, *et al.* Paracrine regulation of the epithelial Na+ channel in
 504 the mammalian collecting duct by purinergic P2Y2 receptor tone. *J Biol Chem* 2008; 283:
 505 36599-36607.
- 50755.Deetjen P, Thomas J, Lehrmann H, et al. The luminal P2Y receptor in the isolated508perfused mouse cortical collecting duct. J Am Soc Nephrol 2000; **11:** 1798-1806.
- 56. Lehrmann H, Thomas J, Kim SJ, et al. Luminal P2Y₂ receptor-mediated inhibition of Na⁺
 absorption in isolated perfused mouse CCD. JAm Soc Nephrol 2002; 13: 10-18.
- 51357.Wildman SS, Marks J, Turner CM, et al. Sodium-dependent regulation of renal amiloride-514sensitive currents by apical P2 receptors. J Am Soc Nephrol 2008; 19: 731-742.
- 51658.Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of517worldwide data. Lancet 2005; 365: 217-223.

51959.Stokes L, Scurrah K, Ellis JA, et al. A loss-of-function polymorphism in the human P2X4520receptor is associated with increased pulse pressure. Hypertension 2011; 58: 1086-1092.

521

524

527

531

535

538

542

546

549

552

555

559

563

- 522 60. Palomino-Doza J, Rahman TJ, Avery PJ, *et al.* Ambulatory blood pressure is associated 523 with polymorphic variation in P2X receptor genes. *Hypertension* 2008; **52:** 980-985.
- 525 61. Gidlof O, Smith JG, Melander O, *et al.* A common missense variant in the ATP receptor 526 P2X7 is associated with reduced risk of cardiovascular events. *PLoS One* 2012; **7**: e37491.
- 528 62. Ghiadoni L, Rossi C, Duranti E, *et al.* P2X7 receptor polymorphisms do not influence 529 endothelial function and vascular tone in neo-diagnosed, treatment-naive essential 530 hypertensive patients. *J Hypertens* 2013; **31:** 2362-2369.
- 63. McHugh SM, Roman S, Davis B, *et al.* Effects of genetic variation in the P2RX7 gene on
 pharmacodynamics of a P2X(7) receptor antagonist: a prospective genotyping approach. *Br J Clin Pharmacol* 2012; **74:** 376-380.
- 536 64. Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. *J* 537 *Physiol* 2014; **592:** 3955-3967.
- 53965.Nishiyama A, Majid DS, Taher KA, et al. Relation between renal interstitial ATP540concentrations and autoregulation-mediated changes in renal vascular resistance. Circ541Res 2000; 86: 656-662.
- 54366.Zhang Y, Robson SC, Morris KL, et al. Impaired natriuretic response to high-NaCl diet plus544aldosterone infusion in mice overexpressing human CD39, an ectonucleotidase545(NTPDase1). Am J Physiol Renal Physiol 2015; **308:** F1398-1408.
- 54767.Rieg T, Bundey RA, Chen Y, et al. Mice lacking P2Y2 receptors have salt-resistant548hypertension and facilitated renal Na⁺ and water reabsorption. FASEB J 2007.
- 550 68. Pandit MM, Inscho EW, Zhang S, *et al.* Flow regulation of endothelin-1 production in the 551 inner medullary collecting duct. *Am J Physiol Renal Physiol* 2015; **308:** F541-552.
- 553 69. Ji X, Naito Y, Hirokawa G, *et al.* P2X(7) receptor antagonism attenuates the hypertension 554 and renal injury in Dahl salt-sensitive rats. *Hypertens Res* 2012; **35:** 173-179.
- Ji X, Naito Y, Weng H, et al. P2X7 deficiency attenuates hypertension and renal injury in
 deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal Physiol 2012; 303:
 F1207-1215.
- 560 71. Masin M, Young C, Lim K, *et al.* Expression, assembly and function of novel C-terminal
 561 truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. *Br J*562 *Pharmacol* 2012; **165**: 978-993.
- 56472.Menzies RI, Unwin RJ, Dash RK, et al. Effect of P2X4 and P2X7 receptor antagonism on565the pressure diuresis relationship in rats. Front Physiol 2013; 4: 305.

- 567 73. Eser A, Colombel JF, Rutgeerts P, et al. Safety and Efficacy of an Oral Inhibitor of the
 568 Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's
 569 Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. Inflamm
 570 Bowel Dis 2015; 21: 2247-2253.
- 57274.Harada H, Chan CM, Loesch A, et al. Induction of proliferation and apoptotic cell death573via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int5742000; 57: 949-958.
- 57675.Turner CM, Tam FW, Lai PC, et al. Increased expression of the pro-apoptotic ATP-577sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial578Transplant 2007; 22: 386-395.
- 58076.Deplano S, Cook HT, Russell R, et al. P2X7 receptor-mediated Nlrp3-inflammasome581activation is a genetic determinant of macrophage-dependent crescentic582glomerulonephritis. J Leukoc Biol 2013; 93: 127-134.
- 58477.Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing585and release. J Immunol 2006; **176:** 3877-3883.
- 58778.Zhao J, Wang H, Dai C, et al. P2X7 blockade attenuates murine lupus nephritis by588inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 2013; 65:5893176-3185.
- 59179.Yan Y, Bai J, Zhou X, et al. P2X7 receptor inhibition protects against ischemic acute592kidney injury in mice. Am J Physiol Cell Physiol 2015; **308:** C463-472.
- 59480.Solini A, Menini S, Rossi C, et al. The purinergic 2X7 receptor participates in renal595inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome596activation. J Pathol 2013; 231: 342-353.
- 59881.Lu D, Insel PA. Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response599in fibroblasts and tissue fibrosis. Am J Physiol Cell Physiol 2014; **306:** C779-788.
- Lu D, Insel PA. Hydrolysis of extracellular ATP by ectonucleoside triphosphate
 diphosphohydrolase (ENTPD) establishes the set point for fibrotic activity of cardiac
 fibroblasts. *J Biol Chem* 2013; **288**: 19040-19049.
- 60583.Chen JB, Liu WJ, Che H, et al. Adenosine-5'-triphosphate up-regulates proliferation of606human cardiac fibroblasts. Br J Pharmacol 2012; 166: 1140-1150.
- 60884.Solini A, Iacobini C, Ricci C, *et al.* Purinergic modulation of mesangial extracellular matrix609production: role in diabetic and other glomerular diseases. *Kidney Int* 2005; **67**: 875-885.
- 61185.Goncalves RG, Gabrich L, Rosario A, Jr., *et al.* The role of purinergic P2X7 receptors in the612inflammation and fibrosis of unilateral ureteral obstruction in mice. *Kidney Int* 2006; **70**:6131599-1606.
- 614

575

579

583

586

590

593

597

600

604

607

- 615 86. Komada T, Usui F, Shirasuna K, et al. ASC in renal collecting duct epithelial cells
 616 contributes to inflammation and injury after unilateral ureteral obstruction. Am J Pathol
 617 2014; 184: 1287-1298.
- 619 87. Guo C, Masin M, Qureshi OS, *et al.* Evidence for functional P2X4/P2X7 heteromeric 620 receptors. *Mol Pharmacol* 2007; **72:** 1447-1456.

621

625

629

633

636

639

642

645

648

652

656

658

- 62288.Antonio LS, Stewart AP, Xu XJ, et al. P2X4 receptors interact with both P2X2 and P2X7623receptors in the form of homotrimers. British Journal of Pharmacology 2011; 163: 1069-6241077.
- Kim MJ, Turner CM, Hewitt R, *et al.* Exaggerated renal fibrosis in P2X4 receptor-deficient
 mice following unilateral ureteric obstruction. *Nephrol Dial Transplant* 2014; **29:** 13501361.
- 630 90. Kohler D, Eckle T, Faigle M, *et al.* CD39/ectonucleoside triphosphate diphosphohydrolase
 631 1 provides myocardial protection during cardiac ischemia/reperfusion injury. *Circulation*632 2007; **116:** 1784-1794.
- 634 91. Grenz A, Zhang H, Hermes M, *et al.* Contribution of E-NTPDase1 (CD39) to renal 635 protection from ischemia-reperfusion injury. *FASEB J* 2007; **21:** 2863-2873.
- 637 92. Roberts V, Lu B, Rajakumar S, *et al.* The CD39-adenosinergic axis in the pathogenesis of 638 renal ischemia-reperfusion injury. *Purinergic Signal* 2013; **9:** 135-143.
- 64093.Rajakumar SV, Lu B, Crikis S, et al. Deficiency or inhibition of CD73 protects in mild641kidney ischemia-reperfusion injury. Transplantation 2010; **90:** 1260-1264.
- 64394.Wang YM, McRae JL, Robson SC, et al. Regulatory T cells participate in CD39-mediated644protection from renal injury. Eur J Immunol 2012; 42: 2441-2451.
- 64695.Gu BJ, Zhang W, Worthington RA, et al. A Glu-496 to Ala polymorphism leads to loss of647function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-11142.
- 649 96. Sluyter R, Shemon AN, Wiley JS. Glu496 to Ala polymorphism in the P2X7 receptor
 650 impairs ATP-induced IL-1 beta release from human monocytes. *J Immunol* 2004; **172**:
 651 3399-3405.
- Ali Z, Laurijssens B, Ostenfeld T, *et al.* Pharmacokinetic and pharmacodynamic profiling
 of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. *Br J Clin Pharmacol* 2013; **75:** 197-207.
- 657 98. Stevens M, Oltean S. Alternative Splicing in CKD. J Am Soc Nephrol 2016; 27: 1596-1603.
- 65999.Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the660use of P2X7 antagonists in models of disease. *Pharmacol Rev* 2014; **66:** 638-675.

- de Torre-Minguela C, Barbera-Cremades M, Gomez AI, *et al.* Macrophage activation and
 polarization modify P2X7 receptor secretome influencing the inflammatory process. *Sci Rep* 2016; **6**:22586.

668 Acknowledgements

- 669 Research in the authors' laboratories was funded by The British Heart Foundation and Kidney
- 670 Research UK.

671 Disclosures

- 672 RJU is currently on secondment as Chief Scientist to Cardiovascular and Metabolic Diseases
- 673 (iMed CVMD) R&D, AstraZeneca, Mölndal, Sweden. FWKT and MAB have received research
- 674 funding from AstraZeneca.
- 675
- 676
- 677
- 678

679 Figure 1: The autocrine / paracrine purinoceptor system

680 A range of stimuli including cellular stretch, trauma, or agonist binding triggers ATP release into 681 the extracellular space. Ectonucleotidases located on the plasma membrane catalyse sequential 682 hydrolysis of ATP to ADP, 5'AMP and adenosine. P1 receptors recognize adenosine while P2 683 receptors bind di- and tri-phosphate nucleotide molecules. P2X receptors are non-selective 684 cation channels with 3 protein subunits that may form homo- or heteromeric arrangements; all 685 bind ATP. P2Y receptors are 7 transmembrane-spanning domain G-protein-coupled receptors; 686 agonist preferences span adenosine and uracil di- and tri- nucleotides. NTPDase: ectonucleoside 687 triphosphate diphosphohydrolase.

688

689 **Figure 2: P2 Receptors in the kidney**

690 P2Y and P2X receptor expression along the nephron: vasculature, glomeruli and tubules.

691

692 Figure 3: P2XR related inflammation in (diabetic) kidney disease


Local production of chemokines, adhesion molecules and inflammatory cytokines are upregulated under chronic stimulation of factors including hyperglycemia. Macrophages are the main infiltrating inflammatory cell type (expressing P2X7R) in both the glomerular and tubulointerstitial compartments where they contribute to extracellular matrix (ECM) secretion, amplification of the inflammatory cascade and eventually fibrosis.

698

699

700

Figure 1






Figure 3

